Lung Cancer Trial, Recruiting (NCT05265429)

Lung Cancer Trial, Recruiting NCT05265429 Sponsor: Dana-Farber Cancer Institute Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05265429 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who were 45 years old or younger when they were diagnosed with lung cancer
People who have been confirmed by laboratory testing to have a type of lung cancer originating in the airways (either non-small cell or small cell lung cancer, at any stage), at any point during their treatment
People who are willing to provide written agreement to participate in the study
People who are willing to have no more than two blood draws within a four-week period, with no more than 50ml of blood collected over eight weeks
People under the age of 18 may be eligible if they meet the defined criteria, provided a parent or legal guardian gives consent on their behalf

Who may not be able to join:

People who decline to sign the consent form
People who are unable to give consent themselves and do not have a designated healthcare proxy or legal guardian to do so on their behalf
People where using tissue samples for research purposes would interfere with accurately diagnosing or determining the stage of their cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pasi A Janne, MD, PhD, Dana-Farber Cancer Institute

Phone: 617-632-6036

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05265429

Sponsor: Dana-Farber Cancer Institute

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: 617-632-6036

More information: https://clinicaltrials.gov/study/NCT05265429

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who were 45 years old or younger when they were diagnosed with lung cancer
People who have been confirmed by laboratory testing to have a type of lung cancer originating in the airways (either non-small cell or small cell lung cancer, at any stage), at any point during their treatment
People who are willing to provide written agreement to participate in the study
People who are willing to have no more than two blood draws within a four-week period, with no more than 50ml of blood collected over eight weeks
People under the age of 18 may be eligible if they meet the defined criteria, provided a parent or legal guardian gives consent on their behalf

Who may not be able to join:

People who decline to sign the consent form
People who are unable to give consent themselves and do not have a designated healthcare proxy or legal guardian to do so on their behalf
People where using tissue samples for research purposes would interfere with accurately diagnosing or determining the stage of their cancer

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Dana-Farber Cancer Institute

Registry

ClinicalTrials.gov

Start date

1 January 2023

Est. completion

1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Repository of specimens and data

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov